-
Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology
•
The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen Inc. (SHA: 688222). This collaboration will leverage HitGen’s DNA-encoded library (DEL) technology platform to screen under-represented targets identified by SGC. The resulting screening datasets will be made available on a publicly accessible portal, enabling global…
-
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
•
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on the Nasdaq exchange last week. The company issued 2.5 million American depositary shares at a price of USD 23 each, resulting in a gross proceeds of USD 57.5 million. In addition, Adlai Nortye secured USD…
-
Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4
•
Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on KRAS and Nectin-4, all of which are currently in the pre-clinical stage. This strategic move highlights Lilly’s commitment to advancing cancer therapies that target specific oncogenic pathways. Details of the New Oncology Programs The new…
-
FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment
•
The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for lebrikizumab, an anti-IL-13 biologic intended for the treatment of moderate-to-severe atopic dermatitis. The company announced the setback this week, highlighting the challenges faced in the regulatory approval process. Background on Lebrikizumab’s Acquisition Eli Lilly acquired…
-
Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas
•
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery specialist Twist Bioscience (NASDAQ: TWST) to develop antibodies targeting undisclosed disease areas. This collaboration is set to enhance Bayer’s capabilities in antibody discovery and development. Financial Terms of the Collaboration Under the terms of the…
-
Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030
•
The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and seven other governmental bodies, has unveiled an “Implementation Plan for Accelerating the Elimination of Cervical Cancer in Beijing (2023-2030).” This ambitious campaign aims to significantly reduce cervical cancer incidence through a series of targeted preventive…
-
ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform
•
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with domestic firm Glyco-Therapy. This collaboration aims to create a comprehensive resource cooperation and service platform for the development of next-generation antibody drug conjugates (ADCs). Innovative Approach to ADC Development The partnership will focus on the…
-
Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China
•
China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand Life Sciences for its monoclonal antibody, KN057. This innovative therapy targets the tissue factor pathway inhibitor (TFPO) and is aimed at treating hemophilia A and hemophilia B in the Greater China region. Agreement Details and…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
